Physician profile
Gregory K Harmon
NPI 1386731479
$3,741.96
in general payments reported to CMS, 2019-2025
21 companies · $702 in 2025
The $702 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $298 · 2021: $532 · 2022: $323 · 2023: $732 · 2024: $815 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,232 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.01 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $610.93 | 2023-2025 | Envista Mx60 Iol, Vyzulta, Xiidra |
| Abbvie INC. | $543.30 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $431.33 | 2021-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Alcon Vision LLC | $344.88 | 2020-2025 | Eysuvis, Tryptyr, Clareon Panoptix Pro |
| Allergan, INC. | $316.48 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $299.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $210.31 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $190.70 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $130.59 | 2023-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $124.39 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $106.95 | 2024-2025 | |
| Amgen INC. | $97.70 | 2024-2025 | Tepezza |
| Thea Pharma INC. | $95.26 | 2025 | Iyuzeh |
| Sight Sciences, INC. | $78.23 | 2020-2022 | |
| Biotissue Holdings INC. | $44.54 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $26.15 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.24 | 2019 | |
| Eyevance Pharmaceuticals LLC | $21.21 | 2019 | |
| Ivantis, INC | $20.97 | 2019 | |
| Horizon Therapeutics Plc | $14.46 | 2021 | |
| Rxsight INC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.